KR20130121795A - Polymorphic marker of ulcerative colitis and crohn’s disease in korean, method of predicting ulcerative colitis or crohn’s disease risk in korean using the genotype information - Google Patents

Abstract

The present invention provides a polymorphic marker for predicting the risk of ulcerative colitis and Crohn’s disease in Koreans. The polymorphic marker for predicting the risk of ulcerative colitis and Crohn’s disease in Koreans is used for predicting the risk of ulcerative colitis or Crohn’s disease as a genetically risk factor for ulcerative colitis or Crohn’s disease which is a lower group of inflammatory bowel diseases in Koreans and as a genetic marker for diagnosing ulcerative colitis or Crohn’s disease.

Description

POLYMORPHIC MARKER OF ULCERATIVE COLITIS AND CROHN'S DISEASE IN KOREAN, METHOD OF PREDICTING ULCERATIVE COLITIS OR CROHN'S DISEASE RIK THE KNOTYPE }

The present invention relates to a polymorphic marker for predicting ulcerative colitis and Crohn's disease risk in Korean, and to a method for predicting colitis or Crohn's disease risk using the same.

Inflammatory bowel disease is a chronic recurrent disease consisting of clinically ulcerative colitis and Crohn's disease. Inflammatory bowel disease occurs mainly in the Jews and Caucasians by race and relatively rarely occurs in Asians. In recent years, however, the incidence rate has increased in other Asian countries, including Southern Europe, Korea, and other developing countries. However, many patients suffer from ulcerative colitis and Crohn's disease, two subgroups of inflammatory bowel disease, but no clear cause or treatment of the disease has been suggested. There are a lot of these difficult problems. Therefore, there may be differences in patient care and treatment methods, and in order to reduce such differences, accurate diagnosis of ulcerative colitis and Crohn's disease is required.

An object of the present invention is to provide a polymorphic marker for predicting Korean ulcerative colitis and Crohn's disease risk.

Another object of the present invention is to provide a method for predicting colitis or Crohn's risk in Korean by using a polymorphic marker for ulcerative colitis and Crohn's disease risk prediction in Korean.

In order to achieve the above object, the present invention provides a polymorphic marker for predicting the risk of ulcerative colitis in Koreans whose 15075th base, which is the single nucleotide polymorphism position of rs2043211 of the CARD8 gene, is T.

According to an embodiment of the present invention, the Korean may be a male in the polymorphic marker for predicting the risk of ulcerative colitis in Koreans.

According to an embodiment of the present invention, the range of distribution of ulcerative colitis in Koreans may be left colitis or pro-colitis in the polymorphic marker for predicting ulcerative colitis risk in Koreans.

In order to achieve the above object, the present invention provides a polymorphic marker for predicting Crohn's disease risk of Koreans whose 1852th base, which is the single nucleotide polymorphism position of rs1972619 of the CARD8 gene, is G.

According to one embodiment of the present invention, the location of the lesion of the Korean Crohn's disease in the polymorphic marker for predicting Crohn's disease risk in Koreans may be the colon, the inflammatory form or the presence of peri anal fistula.

In order to achieve the above object, the present invention provides a polymorphic marker for predicting Crohn's disease risk of Koreans whose 32342 base, which is the single nucleotide polymorphic position of rs4389238 of the CARD8 gene, is T.

According to an embodiment of the present invention, the Korean may be a male in the polymorphic marker for predicting Crohn's disease risk.

According to one embodiment of the present invention, the location of the lesion of Crohn's disease in Korean in the polymorphic marker for predicting the Crohn's disease risk in Korean may be colon.

In order to achieve the above another object, the present invention comprises the steps of separating genomic DNA from a biological sample from a Korean subject; A polymorphic marker for predicting ulcerative colitis risk in Koreans whose 15075th base, which is the rs2043211 of the CARD8 gene on the genomic DNA, is T, where the 1852th base that is the single base polymorphism of rs1972619 of the CARD8 gene is G Predicting ulcerative colitis or Crohn's disease risk comprising detecting a Korean polymorphic marker for predicting Crohn's disease risk or a polymorphic marker for predicting Crohn's disease risk in Koreans having a T nucleotide 32342, the single nucleotide polymorphic position of rs4389238 of the CARD8 gene, as T Provide a method.

The polymorphic marker for predicting ulcerative colitis and Crohn's disease risk in Korean according to the present invention is a genetic risk factor for ulcerative colitis or Crohn's disease, a subgroup of inflammatory bowel disease in Korean. As a marker, it can be usefully used for ulcerative colitis or Crohn's disease prediction method.

EXAMPLES Hereinafter, the present invention will be described in detail with reference to Examples, but it should be understood that the present invention is not limited thereto.

Example

1. Target group

The population according to this embodiment is Korean, 650 patients with Crohn's disease (CD) (441 men, 209 women), 660 patients with ulcerative colitis (UC) (344 men, 316 women). Persons), and 688 normal controls (351 males, 337 females). Patients with Crohn's disease or ulcerative colitis were diagnosed in an inflammatory bowel disease (IBD) clinic of Asan Medical Center according to conventional clinical, radiological, endoscopic and histopathological criteria. Indeterminate colitis (IC), which cannot be classified as Crohn's disease or ulcerative colitis, was excluded from this example. Control groups without specific diseases were recruited from the Health Promotion Center of Asan Medical Center. Slightly improved Montreal classification was used to determine the phenotypic subgroup of Crohn's disease and ulcerative colitis. Two independent investigators (S.K.Y. for Crohn's disease and S.K.Y. and B.D.Y.for ulcerative colitis) were used to classify the genotype analysis without knowing the results. In other words, patients with Crohn's disease were diagnosed at the time of diagnosis (A1: 16 years old, A2: 17-40 years, A3: 40 years old), location of the lesion (L1: ileum, L2: colon; L3). : Subtypes according to the type of colon (ileocolon), the lesions (B1: inflammatory, B2: stricturing, and B3: penetrating). The upper GI invasion and perianal disease modifier were not applied in the Montreal classification. Inflammatory colitis patients are based on colonoscopy findings: maximum endoscopic extent (E1: ulcerative proctitis, E2: left-sided UC, E3: extensive UC). Classified as Demographic and clinical characteristics of the population of this example are shown in Table 1 below.

Crohn's disease (n = 650) Ulcerative Colitis (n = 660) Control group (n = 688) People (N) ratio(%) People (N) ratio(%) People (N) ratio(%) gender - - - - - - male 441 67.8 344 52.1 351 51.0 female 209 32.2 316 47.9 337 49.0 Average age at diagnosis (yr) 24.3 ± 7.7 36.6 ± 12.9 - Age at diagnosis - - - - - - 16 years old or older 63 9.7 21 3.2 - - 17 to 40 years old 560 86.2 374 56.7 530 77.0 Over 40 years old 27 4.1 265 40.2 158 23.0 Location - - - - - - Ileum 123 18.9 - - - - Colon 31 4.8 - - - - Ileocolon 496 76.3 - - - - Distribution - - - - - - Proctitis - - 200 28.2 - - Left-sided UC - - 208 31.7 - - Prostatitis - - 252 37.4 - - Behavior - - - - - - Inflammatory 296 45.5 - - - -  Stricturing 135 20.8 - - - - Penetrating 219 33.7 - - - - perianal fistula - - - - - - No 278 42.8 - - - - Yes 372 57.2 - - - -

This example was approved by the Institutional Review Board of Seoul Asan Hospital, and obtained signature consent from all subjects.

2. SNP genotyping

As a standard method using proteinase K and phenol / chloroform extraction, genomic DNA was isolated from 5 ml of EDTA-anticoagulated venous blood. Genotypes of seven SNPs (rs1965759, rs1062808, rs4389238, rs2288877, rs2043211, rs2288876, rs1972619) were analyzed in CARD8 (caspase recruitment domain-containing protein 8). The rs number refers to the number of the SNP officially registered in the NCBI dbSNP. Genotyping was performed using a matrix-assisted laser desorption / ionization time-of-flight mass spectrometry-based system (Sequenom, San Diego, CA) and performed at the Analytical Genetics Technology Centre, Princess Margaret Hospital / University Health Network (Toronto, Canada). It was.

3. Determination of IL-1β Concentration in Serum

Serum samples were stored at -20 ° C. Quantitative determination of interleukin-1β in serum was performed using human IL-1β ELISA kit II (BD Biosciences, San Diego, USA). As described in the manufacturer's manual, the microtiter plate (BD Biosciences, San Diego, USA) is coated with 100 μl / well of mouse monoclonal antibody against IL-1β. Standard and serially diluted human serum samples were placed in the wells and incubated for 2 hours at room temperature. After washing five times with washing buffer, a secondary antibody biotinylated anti-human IL-1β antibody was added and incubated for 1 hour at room temperature. After washing twice, 100 μl of streptavidin-horseradish peroxidase was added and incubated for 30 minutes at room temperature. Color reaction was performed by adding 100 μl of tetramethyl-benzidine (TMB) substrate solution, and the color reaction was stopped by adding 50 μl of stop solution. Absorbance was measured at 450 nm using an ELISA plate reader. A standard curve is obtained from seven IL-1β standard dilutions, and the IL-1β sample concentration is measured. The detection range of the assay was 1.95 to 125 pg / ml.

4. Statistical analysis

A commercial program, SNP Alyze version 5.0 (Dynacom Co., Yokohama, Japan), was used to investigate the correspondence between the respective population and control genotype frequencies for the values expected for Hardy-Weinberg equilibrium. The relevance relates to permutation correction using PLINK 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) and version 3.2 of the Haploview program (http://www.broadinstitute.org/haploview/haploview). Together, the χ ² test was used to compare allele and genotype frequencies of different groups of subjects.

Allele frequencies were compared between each group and control group using logistic regression to obtain age and gender corrected odds ratio (OR) and 95% confidence interval (CI). . Case - Control analysis (analysis control case) from the p-value (p -value) of 0.2 or less, for a single nucleotide polymorphism (SNP) genotype-phenotype analysis was performed. Logistic session analysis was also performed to examine whether there was a significant association between the phenotype and the lesion phenotype.

Pair-wise linkage disequilibrium (LD) values, D 'and square ( r ² ), and p -values corresponding to the χ ² test were calculated using the SNP Alyze software package and Haploview program version 3.2. The pair-wise association imbalance (LD) between the seven polymorphisms of CARD8 up to 43,349 base pairs (bp) on chromosome 19q13.3 is slightly low (0.08 <R ² <0.51, data not shown). The results of the haplotype analysis were no different from the single marker analysis. Differences in IL-1β levels between various genotype groups were assessed using analysis of variance (ANOVA) and t -tests. When the p value was less than 0.05, it was determined to be statistically significant, and the data was analyzed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL).

5. Results

(1) Analysis of the relationship between inflammatory bowel disease and CARD8 polymorphism in Koreans

Seven monobasic polymorphisms of CARD8 were analyzed for 1,310 inflammatory bowel disease patients (650 Crohn's disease patients and 660 ulcerative colitis patients) and 688 healthy controls. The seven monobasic polymorphisms (SNPs) showed no significant deviation from the Hardy-Weinberg equilibrium. For Koreans, the seven monobasic polymorphisms (SNPs) did not show a significant relationship in the inflammatory bowel disease group. The allele frequency difference range of seven monobasic polymorphisms between the control group and the inflammatory bowel disease patient group was 0.1-1.7%, and did not reach a statistically significant range (data not shown). However, as a result of correlation analysis for the Crohn's disease group and the ulcerative colitis patient group, the six monobasic polymorphisms showed the opposite risk allele and showed statistically relevant relationship with each disease. The monobasic polymorphisms differed from each other (see Tables 2 and 3, where aOR is age and gender calibrated odds ratio, ^a chromosome position, ^b allele 1 is a risk allele, and ^a allele 1 is a risk). Allele). Table 2 is a result of the relationship analysis between CARD8 ulcerative colitis patients and controls, the following Table 3 shows the results of correlation analysis between CARD8 Crohn's disease patients and controls.

ID Position ^a Allele ^b Genotype of Case of UC Patient Group Sum Control genotype of control Sum One 2 11 12 22 11 12 22 rs1965759 53399393 C T 341 (53.7%) 252 (39.7%) 42 (6.6%) 635 302 (51.0%) 249 (42.1%) 41 (6.9%) 592 rs1062808 53403288 G A 173 (27.4%) 314 (49.7%) 145 (22.9%) 632 143 (24.2%) 305 (51.5%) 144 (24.3%) 592 rs4389238 53412251 C T 388 (61.2%) 221 (34.9%) 25 (3.9%) 634 353 (59.7%) 214 (36.2%) 24 (4.1%) 591 rs2288877 53429518 A G 377 (57.8%) 242 (37.1%) 33 (5.1%) 652 388 (57.1%) 244 (35.9%) 48 (7.1%) 680 rs2043211 53429363 T A 150 (22.9%) 318 (48.6%) 186 (28.4%) 654 112 (16.4%) 354 (51.9%) 216 (31.7%) 682 rs2288876 53429576 T C 371 (57.4%) 241 (37.3%) 34 (5.3%) 646 387 (57.1%) 243 (35.8%) 48 (7.1%) 678 rs1972619 53442741 A G 59 (9.5%) 273 (44.0%) 288 (46.5%) 620 52 (8.8%) 237 (40.3%) 299 (50.9%) 588 ID location Allele Allele 1 vs 2 χ ²
( p -value) Genotype 11 vs 22 Genotype 11 + 12 vs 22 Genotype 11 vs 12 + 22 One 2 aOR (95% CI) p -value aOR (95% CI) p -value aOR (95% CI) p -value rs1965759 53399393 C T 0.696 (0.404) 1.191 (0.742-1.911) 0.470 1.119 (0.706-1.775) 0.633 1.157 (0.918-1.458) 0.216 rs1062808 53403288 G A 1.294 (0.255) 1.225 (0.881-1.703) 0.227 1.092 (0.832-1.433) 0.526 1.201 (0.922-1.565) 0.175 rs4389238 53412251 C T 0.226 (0.634) 1.023 (0.564-1.859) 0.936 1.012 (0.561-1.825) 0.969 1.030 (0.814-1.305) 0.804 rs2288877 53429518 A G 0.689 (0.407) 1.492 (0.926-2.403) 0.100 1.502 (0.940-2.398) 0.089 1.043 (0.835-1.302) 0.711 rs2043211 53429363 T A 6.411 (0.011) 1.551 (1.126-2.136) 0.007 1.170 (0.921-1.486) 0.198 1.505 (1.140-1.988) 0.004 rs2288876 53429576 T C 0.420 (0.517) 1.424 (0.888-2.285) 0.143 1.439 (0.905-2.289) 0.124 1.028 (0.823-1.284) 0.807 rs1972619 53442741 A G 1.838 (0.175) 1.178 (0.775-1.791) 0.442 1.172 (0.929-1.479) 0.182 1.095 (0.732-1.639) 0.658

ID Allele ^b Genotype of CD case Sum Control genotype of control Sum One 2 11 12 22 11 12 22 rs1965759 C T 330 (53.14%) 244 (39.29%) 47 (7.57%) 621 302 (51.01%) 249 (42.06%) 41 (6.93%) 592 rs1062808 A G 169 (27.21%) 316 (50.89%) 136 (21.90%) 621 144 (24.32%) 305 (51.52%) 143 (24.16%) 592 rs4389238 T C 45 (7.25%) 226 (36.39%) 350 (56.36%) 621 24 (4.06%) 214 (36.21%) 353 (59.63%) 591 rs2288877 G A 44 (6.79%) 249 (38.43%) 355 (54.78%) 648 48 (7.06%) 244 (35.88%) 388 (57.06%) 680 rs2043211 A T 230 (35.44%) 306 (47.15%) 113 (17.41%) 649 216 (31.67%) 354 (51.91%) 112 (16.42%) 682 rs2288876 C T 44 (6.82%) 246 (38.14%) 355 (55.04%) 645 48 (7.08%) 243 (35.84%) 387 (57.08%) 678 rs1972619 G A 335 (54.65%) 248 (40.46%) 30 (4.89%) 613 299 (50.84%) 237 (40.31%) 52 (8.84%) 588 ID Allele ^b Allele 1 vs 2 χ ²
( p -value) Genotype 11 vs 22 Genotype 11 + 12 vs 22 Genotype 11 vs 12 + 22 One 2 aOR (95% CI) p -value aOR (95% CI) p -value aOR (95% CI) p -value rs1965759 C T 0.167 (0.683) 0.922 (0.568-1.498) 0.743 0.918 (0.573-1.473) 0.724 0.996 (0.781-1.269) 0.972 rs1062808 A G 1.606 (0.205) 1.345 (0.949-1.906) 0.096 1.221 (0.915-1.628) 0.174 1.211 (0.917-1.600) 0.177 rs4389238 T C 3.582 (0.058) 1.923 (1.098-3.367) 0.022 1.139 (0.891-1.457) 0.298 1.883 (1.085-3.269) 0.024 rs2288877 G A 0.352 (0.553) 1.076 (0.668-1.733) 0.764 1.164 (0.919-1.474) 0.208 1.007 (0.632-1.604) 0.978 rs2043211 A T 0.528 (0.467) 1.019 (0.719-1.446) 0.914 0.904 (0.662-1.235) 0.525 1.167 (0.911-1.496) 0.222 rs2288876 C T 0.277 (0.599) 1.074 (0.667-1.729) 0.769 1.155 (0.912-1.464) 0.232 1.009 (0.633-1.607) 0.971 rs1972619 G A 4.569 (0.033) 2.010 (1.212-3.332) 0.007 1.994 (1.217-3.266) 0.006 1.123 (0.880-1.433) 0.350

(2) Analysis of the Relationship between Ulcerative Colitis (UC) and Polymorphism of CARD8 in Koreans

The genotype distribution of seven monobasic polymorphisms in the ulcerative colitis patient group is shown in Table 2 above. The results are expressed as gender and age corrected odds ratios (OR) using logistic regression analysis. Seven SNP an analysis of the genotype, rs2043211 that is, the most significant for the single nucleotide polymorphism (C10X) ulcerative colitis patients and allele frequencies (4.9%) among the control group, which results in a variation of the CARD8 protein expression Difference ( P = 0.011). By the way, the difference between the control group and Crohn's disease group was 1.4% in the opposite direction (see Table 3). The difference in the stop allele frequency between the Crohn's disease group and the ulcerative colitis patient group was 6.3%, which was statistically significant ( P = 0.0013). Compared to the AA genotype, the corrected odds ratio (OR) of the rs2043211 of the TT genotype was 1.55 (95% confidence interval (CI) = 1.13-2.14, P = 0.007).

Gender relevance analysis was performed. The only marker showing a statistically significant difference in allele frequency between male and female was rs2043211. The difference was 6.8% in men and 2.7% in women, which was statistically significant only in men ( P = 0.0011). Compared to the AA genotype, the corrected odds ratio (OR) of the rs2043211 of the TT genotype was 1.80 (95% confidence interval (CI) = 1.16-2.78, P = 0.008) in men and 1.32 (95% confidence interval (CI) in women ) = 0.82-2.14, P = 0.256), indicating that the increased risk of ulcerative colitis appears only in men.

(3) Analysis of the relationship between Crohn's disease (CD) and polymorphism of CARD8 in Koreans

The genotype distribution of seven monobasic polymorphisms in Crohn's disease patient group is shown in Table 3 above. The results are expressed as odds ratios (relative risk) for gender and age-corrected disease using logistic regression analysis.

Χ ² test results for comparing allele and genotype frequencies between Crohn 's disease patients and controls showed marginal significance for rs1972619 located at intron 1 of CARD8 ( P = 0.033, P = respectively). 0.022). The difference in allele frequency between the control group and Crohn's disease group was 3.9%. However, the difference between the control group and the ulcerative colitis patient group was 2.6% in the opposite direction (see Table 2). Therefore, the difference in rs1972619 allele frequency between the Crohn's disease group and the ulcerative colitis patient group was 6.5%, which was statistically significant ( P = 4.0 × 10 ⁻⁴ ). The corrected odds ratio (OR) of the rs1972619 of the GG genotype was 2.01 when compared to the AA genotype (95% confidence interval (CI) = 1.21-3.33, P = 0.007). Another monobasic polymorphism located in intron 8, ie rs4389238, showed a 3.3% difference in allele frequency between the control and Crohn's disease patients. The minor allele of rs4389238 showed marginal association of Crohn's disease with a recessive model (OR = 1.92, 95% confidence interval (CI) = 1.10-3.37, P = 0.022) On the other hand, the nonsynonymous SNPs, ie rs2043211, showed no significance for Crohn's disease, and the frequency of Cys alleles, leading to mutations in protein expression that were significantly associated with ulcerative colitis. It was higher in the Crohn's disease group than in the control group (0.590 vs. 0.576).

According to gender-related relationships, rs4389238 was the only marker that showed a weak significant difference in allele frequency between male and female. The difference was 4.6% in males and 2.6% in females, showing only the significance of the border level in males only ( P = 0.041). Compared to the CC genotype, the corrected odds ratio (OR) of the rs4389238 of the TT genotype was 3.09 (95% confidence interval (CI) = 1.30-7.32, P = 0.011) in men and 1.25 (95% confidence interval (CI) in women ) = 0.56-2.76, P = 0.59), indicating that the increased risk of Crohn's disease appears in men.

(4) CARD8 polymorphism and clinical phenotype of ulcerative colitis (UC)

The relationship between the clinical phenotype of ulcerative colitis and the seven monobasic polymorphisms was evaluated. Risk allele frequency of rs 2043211 for left colitis or procolitis (5.6% for left colitis ( P = 0.043) and 5.6% for procolitis ( P = 0.030), see Table 4) (risk allele Frequency marginal difference was observed statistically. According to the combined subtype analysis of left colitis and procolitis, the association was statistically significant and confirmed by 1,000 permutation test ( P = 0.043). Table 4 below shows the analysis results of genotype frequency and allele frequency of rs2043211 in the ulcerative colitis patient group stratified by the distribution range of the lesion.

rs2043211
(T = 1, A = 2) Control group Proctitis P Left colitis P Prostatitis P Left colitis + pro colitis P Genotype frequency

11 112/682
(16.4%) 45/199
(22.6%) 0.045 49/204
(24.0%) 0.014 56/251
(22.3%) 0.038 105/455
(23.1%) 0.005 12 354/682
(51.9%) 91/199
(45.7%) 0.125 98/204
(48.0%) 0.332 129/251
(51.4%) 0.890 227/455
(49.9%) 0.505 22 216/682
(31.7%) 63/199
(31.7%) 0.997 57/204
(27.9%) 0.311 66/251
(26.3%) 0.113 123/455
(27.0%) 0.094 Allele One 578/1364
(42.4%) 181/398
(45.5%) 0.272 196/408
(48.0%) 0.043 241/502
(48.0%) 0.030 437/910
(48.0%) 0.008

(5) Polymorphism of CARD8 and Clinical Phenotype of Crohn's Disease (CD)

The relationship between the clinical phenotype of Crohn's disease and the seven monobasic polymorphisms was evaluated. As shown in Table 5, except for rs1972619 and rs4389238, there was no significant difference in allele frequency between subgroups of Crohn's disease stratified by the location and expression of the lesion.

There was a statistically significant borderline difference (4.0%, P = 0.028) in the risk allele frequency between Crohn's disease group and control group invading the ileocolon of rs4389238, and Crohn's disease patients with rs1972619 , Statistically no boundary level difference in risk allele frequency between Crohn's disease group or control group without control group or control group (Colon disease: 4.3%, P = 0.029, Inflammatory: 5.4%, P = 0.018, anal fistula absence: 4.9%, P = 0.039). However, the significance was not confirmed by 1,000 permutation test. The corrected odds ratio (OR) for the association of rs1972619 in Crohn's disease group, inflammatory Crohn's disease group, or Crohn's disease patient without peri-anal fistula, was 2.02 (95% confidence interval (CI) = 1.16-3.50). , P = 0.013), 2.94 (95% confidence interval (CI) = 1.41-6.12, P = 0.004), 2.58 (95% confidence interval (CI) = 1.26-5.28, P = 0.010). Table 5 below shows the analysis results of genotype and allele frequency of CARD8 variants in the Crohn 's disease group stratified by control and lesion location and expression. In Table 5, ML1 represents the ileum, ML2 represents the colon, ML3 represents the colon, and ML1 represents the ileum, and MB1 represents the inflammatory and MB2 stenosis. (stricturing), MB3 represents penetrating, and allele 1 represents a risk allele.

rs4389238
(T = 1, C = 2) Control group ML1 P ML2 P ML3 P Genotype frequency 11 24/591 (4.1%) 9/119 (7.6%) 0.098 4/29 (13.8%) 0.014 32/473 (6.8%) 0.050 12 214/591 (36.2%) 35/119 (29.4%) 0.156 7/29 (24.1%) 0.185 184/473 (38.9%) 0.367 22 353/591 (59.7%) 75/119 (63.0%) 0.503 18/29 (62.1%) 0.802 257/473 (54.3%) 0.077 One 262/1182 (22.2%) 53/238 (22.3%) 0.972 15/58 (25.9%) 0.509 248/946 (26.2%) 0.030 Control group MB1 P MB2 P MB3 P Genotype frequency 11 24/591 (4.1%) 26/280 (9.3%) 0.002 6/132 (4.6%) 0.801 13/209 (6.2%) 0.201 12 214/591 (36.2%) 95/280 (33.9%) 0.511 48/132 (36.4%) 0.973 83/209 (39.7%) 0.368 22 353/591 (59.7%) 159/280 (56.8%) 0.410 78/132 (59.14%) 0.893 113/209 (54.1%) 0.154 One 262/1182 (22.2%) 147/560 (26.3%) 0.060 60/264 (22.7%) 0.843 109/418 (26.1%) 0.103 rs2043211
(A = 1, T = 2) Control group ML1 P ML2 P ML3 P Genotype frequency 11 216/682 (31.7%) 36/122 (29.5%) 0.635 14/31 (45.2%) 0.116 180/496 (36.3%) 0.098 12 354/682 (51.9%) 61/122 (50.0%) 0.698 14/31 (45.2%) 0.462 231/496 (46.6%) 0.071 22 112/682 (16.4%) 25/122 (20.5%) 0.271 3/31 (9.7%) 0.318 85/496 (17.1%) 0.745 One 786/1364 (57.6%) 133/244 (54.5%) 0.365 42/62 (67.7%) 0.114 591/992 (59.6%) 0.343 Control group MB1 P MB2 P MB3 P Genotype frequency 11 216/682 (31.7%) 119/296 (40.2%) 0.010 49/135 (36.3%) 0.294 62/218 (28.4%) 0.369 12 354/682 (51.9%) 125/296 (42.2%) 0.005 66/135 (48.9%) 0.522 115/218 (52.8%) 0.828 22 112/682 (16.4%) 52/296 (17.6%) 0.660 20/135 (14.8%) 0.643 41/218 (18.8%) 0.414 One 786/1364 (57.6%) 363/592 (61.3%) 0.127 164/270 (60.7%) 0.343 239/436 (54.8%) 0.303 rs1972619
(G = 1, A = 2) Control group ML1 P ML2 P ML3 P Genotype frequency 11 299/588 (50.9%) 59/119 (49.6%) 0.800 17/29 (58.6%) 0.414 259/465 (55.7%) 0.117 12 237/588 (40.3%) 54/119 (45.4%) 0.305 12/29 (41.4%) 0.908 182/465 (39.1%) 0.701 22 52/588 (8.8%) 6/119 (5.0%) 0.168 0/29 (0.0%) 0.094 24/465 (5.2%) 0.022 One 835/1176 (71.0%) 172/238 (72.3%) 0.694 46/58 (79.3%) 0.172 700/930 (75.3%) 0.029 Control group MB1 P MB2 P MB3 P Genotype frequency 11 299/588 (50.9%) 156/276 (56.5%) 0.120 74/131 (56.5%) 0.243 105/206 (51.0%) 0.976 12 237/588 (40.3%) 110/276 (39.9%) 0.900 51/131 (38.9%) 0.772 87/206 (42.2%) 0.628 22 52/588 (8.8%) 10/276 (3.6%) 0.006 6/131 (4.6%) 0.105 14/206 (6.8%) 0.360 One 835/1176 (71.0%) 422/552 (76.4%) 0.018 199/262 (76.0%) 0.107 297/412 (72.1%) 0.676

(6) Measurement of IL-1β Concentration in Serum

To investigate the functional significance of single nucleotide polymorphism (SNP) rs2043211 (C10X), which causes mutations in protein expression, to determine the association with genotypes, 70 controls, 107 patients with Crohn's disease, 106 patients with ulcerative colitis Levels in serum of IL-1β were measured. The level of IL-1β is Crohn's disease group (7.0 ± 17.3 pg / ml) or ulcerative colitis compared to the control group (0.97 ± 6.8 pg / ml for both Crohn's and ulcerative colitis patients, P = 0.01). The patient group (4.9 ± 8.4 pg / ml) was significantly higher. However, the difference between the ulcerative colitis patient group and Crohn's disease patient group did not reach a statistically significant level ( P = 0.265). According to the analysis of variance (ANOVA) between ulcerative colitis patients and Crohn's disease patients, the ulcerative colitis patients group (TT: 6.6 ± 11.9, TA: 5.3 ± 4.1, AA: 2.8 ± 4.8, P = 0.116) or Crohn's disease group (TT: 4.1 ± 9.7, TA: 12.9 ± 29.5, AA 5.5 ± 10.1, P = 0.114) IL-1β levels in serum were statistically significant between the three genotypes of rs2043211 There was no difference. As shown in Table 8, the combined analysis of heterozygote and homozygote revealed a positive correlation between the stop allele frequency of rs2043211 and high serum IL-1β levels. Positive correlation was observed only in ulcerative colitis (TT + AT: 6.1 ± 9.8 pg / ml, AA: 2.8 ± 4.8 pg / ml, P = 0.048). In the ulcerative colitis patients group, a more significant association was observed in the gender analysis. In female patients in the ulcerative colitis group, there was a significant difference in serum IL-1β levels between the three genotypes of rs2043211 ( P = 0.027). Table 6 below shows the results for mean serum IL-1β levels according to the genotype of rs2043211, where ^a allele 1 is a risk allele.

ID Allele
(allele ^a ) UC One 2 11
(N) 12
(N) 22
(N) 11 + 12
(N) 12 + 22
(N) 11 vs 12 vs 22
P 12 to 22
P 11 to 22
P 11 + 12 vs 22
P 11 vs 12 + 22
P rs2043211 T A Sum 6.639
(43) 5.254
(24) 2.793 (39) 6.143
(67) 3.731 (63) 0.116 0.041 0.055 0.048 0.133 male 3.997
(21) 4.990
(11) 5.176
(15) 4.338
(32) 5.097
(26) 0.824 0.936 0.592 0.658 0.535 female 9.161
(22) 5.479 (13) 1.303
(24) 7.793
(35) 2.770
(37) 0.027 0.003 0.025 0.004 0.064

Claims (2)

A composition for predicting Crohn's disease risk in Korean comprising a polymorphic marker having a G of the 1852 base, which is the mononucleotide polymorphic position of rs1972619 of the CARD8 gene. The composition for predicting Crohn's disease risk in Korean according to claim 1, wherein the location of Crohn's disease in Korean is colon colon, and the form of expression is inflammatory or absent peri-anal fistula.